Abstract
Large Language Models (LLM) are AI tools that can respond human-like to voice or free-text commands without training on specific tasks. However, concerns have been raised about their potential racial bias in healthcare tasks. In this study, ChatGPT was used to generate healthcare-related text for patients with HIV, analyzing data from 100 deidentified electronic health record encounters. Each patient’s data were fed four times with all information remaining the same except for race/ethnicity (African American, Asian, Hispanic White, Non-Hispanic White). The text output was analyzed for sentiment, subjectivity, reading ease, and most used words by race/ethnicity and insurance type. Results showed that instructions for African American, Asian, Hispanic White, and Non-Hispanic White patients had an average polarity of 0.14, 0.14, 0.15, and 0.14, respectively, with an average subjectivity of 0.46 for all races/ethnicities. The differences in polarity and subjectivity across races/ethnicities were not statistically significant. However, there was a statistically significant difference in word frequency across races/ethnicities and a statistically significant difference in subjectivity across insurance types with commercial insurance eliciting the most subjective responses and Medicare and other payer types the lowest. The study suggests that ChatGPT is relatively invariant to race/ethnicity and insurance type in terms of linguistic and readability measures. Further studies are needed to validate these results and assess their implications.
Competing Interest Statement
JJH provides clinical AI consultation services to Pieces Technologies, Inc.
Funding Statement
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1 TR003163. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH (National Institutes of Health) (National Institutes of Health).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
100 randomly selected deidentified encounters data; the data was previously structured from a deidentified database for an analysis recently published here: https://pubmed.ncbi.nlm.nih.gov/37577110/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: john.hanna{at}utsouthwestern.edu
↵† Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1 TR003163. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH (National Institutes of Health) (National Institutes of Health).
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.